Abstract
This Chinese expert consensus focuses on the hematoporphyrin derivative (HpD) photodynamic therapy (PDT) in cervical high-grade squamous intraepithelial lesion (HSIL).
Introduction
Cervical cancer remains a significant health burden in China, ranking as the fifth most prevalent cancer among women. The standard of care for high-grade squamous intraepithelial lesions (HSIL)—the immediate precursor to cancer—typically involves surgical procedures like the loop electrosurgical excision procedure (LEEP) or cold-knife coning (CKC). While effective, these surgeries physically alter the cervix, potentially leading to complications such as cervical stenosis or "cervical incompetence," which increases the risk of preterm birth or infertility. As the age of HSIL diagnosis trends younger, there is an urgent need for "organ-saving" treatments that eliminate diseased tissue without compromising reproductive function.
This expert consensus establishes a standardized clinical framework for using systemic hematoporphyrin derivative (HpD) photodynamic therapy (PDT) to treat HSIL. By leveraging a targeted photochemical reaction, HpD-PDT offers a non-invasive, organ-sparing alternative to traditional surgery.
Methods and Mechanism of Action
The consensus defines a standardized protocol for HpD-PDT, which utilizes a systemic photosensitizer (HpD, trade name HiPorfin) injected intravenously. The procedure follows a specific "three-element" photochemical approach:
- Photosensitizer: HpD is administered at a dose of 2 mg/kg. It preferentially accumulates in rapidly proliferating diseased cells.
- Light Source: 48–72 hours after injection, when the concentration gradient between diseased and healthy tissue is highest, a 630 nm diode laser is applied.
- Oxygen: The laser triggers the photosensitizer to transfer energy to local oxygen molecules, generating singlet oxygen ($^1O_2$) and other reactive oxygen species (ROS) that induce selective cell death and vascular shutdown in the lesion.
The protocol specifies distinct irradiation parameters for the cervical canal (columnar fiber) and the cervical surface (flat-cut fiber) to ensure comprehensive coverage, particularly for complex Type 3 transformation zones.
Clinical Evidence and Key Results
The consensus aggregates results from multiple clinical studies evaluating the efficacy and safety of HpD-PDT. Key findings include:
- High Cure Rates: Complete response (CR) rates for CIN II/III lesions typically range from 77.4% to 100% at 12-month follow-up.
- HPV Clearance: The therapy shows strong antiviral effects, with high-risk HPV eradication rates reaching up to 92.7%.
- Non-Inferiority to Surgery: Retrospective comparisons with LEEP show no significant difference in cure rates, but PDT patients reported fewer long-term structural complications.
- Safety: Adverse events are generally mild, consisting of transient lower abdominal pain and manageable skin photosensitivity.
Key Insights
- Systemic Superiority: Unlike topical PDT (5-ALA), which has limited penetration depth, systemic HpD-PDT overcomes "depth of necrosis" limitations, making it suitable for deep-seated lesions.
- Dosage Optimization: The consensus confirms that a lower dose of 2 mg/kg maintains high therapeutic efficacy while significantly reducing the severity and duration of skin photosensitivity compared to historical 5 mg/kg doses.
- Fertility Preservation: A standout benefit is reproductive safety. Patients treated with PDT achieved successful term pregnancies without the increased risk of cervical incompetence associated with surgical conization.
Limitations and Future Directions
The primary drawback of HpD-PDT is systemic photosensitivity. Patients must strictly avoid direct sunlight and strong indoor lighting for 1–2 months post-injection. While current data is promising, the authors acknowledge the need for more high-quality, prospective evidence. An ongoing national multicenter project (ChiCTR2500102685) is expected to provide more robust data to further refine these guidelines. Future research may also explore combining PDT with immunotherapies to enhance HPV clearance.
Summary updated